First-hand accounts of the care that was delivered during the 2013-16 West African outbreak of Ebola virus disease provided impetus for these guidelines.
Two vaccines to prevent Ebola virus disease demonstrated immune responses at 1 month.
An Ebola virus vaccine, rVSVΔG-ZEBOV-GP, provided 100% protection against Ebola in a prior phase 3 trial. A new study reports long-term safety data and shows that the vaccine induces an antibody response for at least 1 year.
A small percentage of Ebola virus survivors have a novel retinal lesion as a result of the disease.
The number of suspected Ebola cases in the Democratic Republic of Congo has risen to 37.
A strategy of preemptive use of an AD26.ZEBOV followed by MVA-BN-Filo immunization schedule in at-risk populations may offer advantages over reactive use of single-dose vaccine regimens.
Changes in messenger RNA abundance proved to be a reliable means of predicting patient's chances of surviving Ebola virus disease.
A new vaccine for Ebola showed high efficacy in preventing the development of Ebola in clusters of people exposed to the virus, and protection was also conferred to those who were not vaccinated.
Liberia's Men's Health Screening Program for Ebola survivors successful in spite of complex challenges.
Virus is more likely to be found in male survivors older than 40, researchers report.
The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of a candidate vaccine that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Generic HIV Medicines: Boon or Bust?
- Insulin-Treated Diabetes Reduces Dysglycemia-Related Mortality in Sepsis
- It Costs $2.2 Billion a Year to Treat Antibiotic Resistance
- Tricyclic Antidepressants May Reduce Cirrhosis Risk in Hepatitis C
- Pregnancy May Be Independently Associated With Prolonged Detection of Zika Virus RNA
- Clostridium difficile Infection in the Intensive Care Setting
- Combating Medically Important Antibiotic Use in Food-Producing Animals
- Religious Exemptions vs Mandatory Vaccinations: An Expert Perspective
- 2018 Vaccination Schedule: Adults
- Fingerstick Point-of-Care Test Allows for Single-Visit HCV Diagnoses
- Glecaprevir/Pibrentasvir Highly Efficacious for HCV/HIV Coinfection
- Fluoroquinolone Use May Increase Risk for Aortic Aneurysm and Dissection
- Reduced Risk of Hepatocellular Carcinoma in DAA-Treated HCV Infection
- Paracetamol Overuse During Cold and Flu Season
- C difficile Risk Higher With Stoma Reversal vs Colectomy